Yuhan Corporation Receives Second Milestone from Janssen for Lazertinib
[Asia Economy Reporter Cho Hyun-ui] Yuhan Corporation announced on the 23rd that it will receive the second milestone payment of $65 million (approximately 72.3 billion KRW) for the lung cancer drug 'Lazertinib,' which was licensed out to the multinational pharmaceutical company Janssen.
Lazertinib is a targeted therapy being developed for first-line treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations or second-line treatment of NSCLC patients with the EGFR T790M mutation.
This milestone payment follows the initiation of Phase 3 clinical trials for the combination therapy of Lazertinib and Janssen's 'Amivantamab.'
Yuhan Corporation licensed Lazertinib, a treatment for non-small cell lung cancer, to Janssen in November 2018 and has been co-developing the drug since then. The total contract value at that time was 1.4 trillion KRW.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Yuhan Corporation is also continuing the development of Lazertinib as a monotherapy for non-small cell lung cancer patients. Currently, a multinational Phase 3 clinical trial is underway to confirm its efficacy and safety as a first-line treatment.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
